BEACOPP escalated
Phase 3Small molecule
BEACOPP escalated is one of 55 small molecule programs targeting Hodgkins lymphoma. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
74 competitors in Hodgkins Lymphoma
#DrugCompanyPhaseTrials
1Adriamycin
PfizerApproved
Cytosar
TevaApproved
Eloxatin
TevaApproved
Velban
Eli LillyApproved
Afinitor
NovartisApproved
Leukeran
Akero TherapeuticsApproved
Zoladex
TTerSera Therapeutics LLC
Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Grafapex
MMedexus Pharma, Inc.
Approved
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BEACOPP escalated. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Cologne